ortho-IL-2 does not lead to the activation of NK cells or systemic activation of T cells in mouse models and this data supports the idea that restricting the activity of IL-2 to tumor-antigen specific T cells via other engineering strategies can deliver significant anti-tumor efficacy. Here, IL2 is linked to neoplasm.